 |
| CLICK HERE TO VIEW CURRENT ISSUE |
 |
| Best of NAMA 2026 |
|
 |
|
FRENCH VACCINE MANUFACTURER BIOVAC LABORATORIES ACQUIRED BY CEVA ANIMAL HEALTH
Jun. 14, 2016
Feedstuffs magazine reports:
Ceva Sante Animale announced the purchase of Biovac Laboratories, a leading manufacturer of autogenous (bacterial) vaccines, allergy treatments and reagents based in Angers, France.
Biovac, like Ceva, has experienced double-digit growth for several years as veterinarians seek alternatives to control bacterial conditions that are often difficult to treat with "classic" antibiotherapy. The company has significant expertise in microbiology, allowing it to provide custom-made solutions for veterinarians and their customers.
Ceva already offers custom vaccines to leading poultry and swine producers in other parts of the world. The strategy is in line with Ceva's stated antimicrobial resistance policy of putting the veterinarian back at the center of the fight against microbial diseases.
Autogenous vaccines are produced only after a qualified veterinarian has identified and diagnosed the disease serotype. In cases where a "standard vaccine" will not be effective, custom vaccines can be produced and prescribed by the veterinarian in four to five weeks, creating an extremely reactive and precise service for livestock producers.
Ceva chairman and chief executive officer Dr. Marc Prikazsky said, "As a veterinarian, I know how disappointing it can be to make a diagnosis and then not have the precise tool necessary to control the disease. Biovac provides an extraordinary service to the veterinarians in France. Through this partnership, we will share all our expertise in vaccine production and new technologies so that, together, we can provide veterinarians in new markets with an even better service."
Established in 1999, Ceva is a global veterinary group involved in research, development, production and marketing of pharmaceutical products and vaccines for companion and farm animals (ruminants, pigs and poultry). With a presence in more than 110 countries, Ceva has averaged double-digit growth since its creation to reach a turnover of 857 million euros in 2015.
|
|
|
|
|
